In the glioma context, Rohle et al. demonstrated that inhibition of mutant IDH by using a small IDH mutant selective inhibitor, AGI-5198, hampered the in vitro and in vivo growth of an oligodendroglioma cell line (TS603), harbouring an endogenous IDH1-R132H mutation. This evidence concerns the gene IDH2 and central nervous system cancer.